The global Radiopharmaceutical market garnered revenue around USD 3.8 Billion in 2019 and projected to reach USD 5.3 Billion in 2027, with at a compound annual growth rate (CAGR) 4.2% throughout the estimate period from 2020 to 2027. Some of the factors driving the radiopharmaceutical market are expansion activities of key radiopharma players; applications in clinical trials; and increase in aging population, pipeline assessment of new drugs, and disease indication mortality. Shutdown of some of the nuclear reactors has led to the development of cyclotron as an alternate source of production of radioisotopes. Increase in prevalence of cancer and rise in demand for nuclear scans for precise diagnosis are among the key factors driving the expansion of the radiopharmaceutical market. Additionally, cost advantage over outsourced radioactive tracers and accessibility of technologically advanced diagnostic devices such as positron emission tomography scan (PET/CT) and a single-photon emission computerized tomography (SPECT) are playing a crucial role in propelling the radiopharmaceutical market.
Radiopharmaceutical products are made of radioactive agents, which are required to be handled by experts for treating cancer and other diseases. Hence, patients prefer treatment available in hospitals. Another reason for this preference is that new diagnostic systems are easily available due to government initiatives.
This research report encompasses precise assessment of the market with the help of comprehensive qualitative insights and supportable prognoses regarding market size, consumption and production. The projections presented in the report have been derived using proven research methodologies and assumptions. It does so by means of comprehensive qualitative insights, historical statistics, and verifiable predictions about market revenue and sales.
The rapidly budding threat owed to the eruption of COVID-19 is impacting lives, communities, businesses, and industries across the globe. With businesses shuttered, flights grounded, COVID-19 is about to affect the global economy in different ways such as by directly upsetting production and demand, by generating supply chain disruption, and by its financial impact on firms and financial markets. Therefore, this report covers COVID-19 outbreak impact analysis on the Radiopharmaceutical market under the research study. The market estimates offered in the report are the outcome of in-depth extensive secondary research, primary interviews and in-house professional assessments. These market evaluations have been measured by reviewing the impact of numerous social, political and economic factors coupled with recent market dynamics affecting the Radiopharmaceutical market growth.
The global Radiopharmaceutical market is characterized by the presence of numerous small as well as medium scale companies. These players are largely focused towards forward integration via raw material production, product manufacturing, and distribution across various industry verticals. The report recognizes numerous crucial manufacturers of the market. This research study aids to comprehend the strategies and associations that companies are converging to survive in this competitive marketplace. This report assists in understanding footprints of the manufacturers with the help of their global revenue, production, capacity and average selling price analysis for period 2016-2027.
Major manufacturers analysed under this study comprises:
the global radiopharmaceutical market include GE Healthcare, Lantheus Medical Imaging, Inc., Mallinckrodt, Siemens Healthineers, Advanced Accelerator Applications, Bayer AG, Eckert & Ziegler, IBA Radiopharma Solutions, Philips, and Jubilant Life Sciences Limited.
This report delivers market breakdown and its revenue, consumption, production analysis and projections by categorizing it depending on parameters such as type, application/end-user, and region. This research report delivers the analysis and prognosis of revenue, production, price, market share and growth trend for different products such as:
Global Radiopharmaceutical Market: Segmentation
Radiopharmaceutical Market, by Source
- Nuclear Reactors
- Cyclotrons
Radiopharmaceutical Market, by Radioisotope
- Technetium-99
- Gallium-67
- Iodine-123
- Iodine-125
- 18F
- Rubidium-82
- Yttrium-90
- Lutetium-177
- Others
Radiopharmaceutical Market, by Application
- Gastro-intestinal
- Oncology
- Nephrology
- Cardiology
- Neurology
- Inflammation
- Others
Radiopharmaceutical Market, by Type
- PET/CT
- SPECT
- Therapeutics
Radiopharmaceutical Market, by End-user
- Hospitals
- Ambulatory Surgical Centers
- Diagnostic Centers
- Cancer Research Institutes
- Others
Regional Analysis and Forecast
Further, this research study analyses market size, production, consumption and its advancement trends at global, regional, and country level for period 2016 to 2027 and covers following region in its scope:
- North America
- Europe
- Germany
- United Kingdom
- Italy
- France
- Rest of EU
- Asia Pacific
- China
- India
- Japan
- Southeast Asia
- Rest of APAC
- Central & South America
- Brazil
- Argentina
- Rest of Central & South America
- Middle East and Africa
- UAE
- Saudi Arabia
- Rest of MEA
Request Customization
Get a Sample
Get a Sample
Request Customization